Sentynl Theraps Inc Drug Patent Portfolio
Sentynl Theraps Inc owns 3 orange book drugs protected by 6 US patents Given below is the list of Sentynl Theraps Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8828356 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | 17 Oct, 2025 | Active |
| US7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | 26 Jul, 2025 | Active |
| US7504095 | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency | 31 Jan, 2025 | Active |
| US6759059 | Fentanyl composition for the treatment of acute pain | 24 Sep, 2019 | Expired |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
| US7910132 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
Latest Legal Activities on Sentynl Theraps Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sentynl Theraps Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Requirement for information sent under 37 CFR 1.750 | 08 Jul, 2024 | US7838531 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US7504095 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2024 | US7838531 |
| transaction for FDA Determination of Regulatory Review Period | 27 Dec, 2023 | US7838531 |
|
Expire Patent
Critical
| 24 Apr, 2023 | US7910132 (Litigated) |
| Second letter to regulating agency to determine regulatory review period | 10 Mar, 2023 | US7838531 |
| Second letter to regulating agency to determine regulatory review period | 14 Feb, 2023 | US7504095 |
| Letter from FDA or Dept of Agriculture re PTE application | 09 Nov, 2022 | US7838531 |
|
Maintenance Fee Reminder Mailed
Critical
| 07 Nov, 2022 | US7910132 (Litigated) |
| Letter from FDA or Dept of Agriculture re PTE application | 21 Sep, 2022 | US7504095 |
|
Email Notification
Critical
| 11 May, 2022 | US7504095 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 11 May, 2022 | US7504095 |
|
Correspondence Address Change
Critical
| 10 May, 2022 | US7504095 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2022 | US7838531 |
| Initial letter Re: PTE Application to regulating agency | 25 Feb, 2022 | US7504095 |
Sentynl Theraps Inc's Family Patents
Sentynl Theraps Inc Drug List
Given below is the complete list of Sentynl Theraps Inc's drugs and the patents protecting them.
1. Abstral
Abstral is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6759059 | Fentanyl composition for the treatment of acute pain |
24 Sep, 2019
(5 years ago)
| Expired |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(5 years ago)
| Expired |
| US7910132 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abstral's drug page
2. Nulibry
Nulibry is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7504095 | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
31 Jan, 2025
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nulibry's drug page
3. Zokinvy
Zokinvy is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8828356 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
17 Oct, 2025
(a year from now)
| Active |
| US7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
26 Jul, 2025
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zokinvy's drug page